Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. O'Reilly
    O'Reilly
  5. Rosenberg
    Rosenberg
  6. Saltz
    Saltz
  7. Janjigian
    Janjigian
  8. Paik
    Paik
  9. Scher
    Scher
  10. Riely
    Riely

Groups

  1. Department of Medicine (1393)
  2. Solid Tumor Oncology Division (1292)
  3. Gastrointestinal Oncology Service (320)
  4. Genitourinary Oncology Service (301)
  5. Thoracic Oncology (277)
  6. GSK Faculty (193)
  7. Hematologic Malignancies, Division of (170)
  8. Survivorship Research (160)
  9. Breast Medicine Service (158)
  10. Center for Pancreatic Cancer Research (132)
Search Within
  1. "Annals of Oncology"
Formats
  1. Meeting Abstract (1227)
  2. Journal Article (372)
  3. Guidelines (19)
  4. Editorial (16)
  5. Review (16)
  6. Conference Paper (8)
  7. Correspondence (4)
  8. Research Letter (1)
Groups
  1. Department of Medicine (1393)
  2. Solid Tumor Oncology Division (1292)
  3. Gastrointestinal Oncology Service (320)
  4. Genitourinary Oncology Service (301)
  5. Thoracic Oncology (277)
  6. GSK Faculty (193)

More Groups

People
  1. Alexander Drilon (94)
  2. Robert Motzer (80)
  3. Ghassan Abou-Alfa (53)
  4. Matthew Hellmann (49)
  5. Eileen O'Reilly (48)
  6. Yelena Janjigian (44)

More People

Years
  1. 2025 (11)
  2. 2024 (147)
  3. 2023 (154)
  4. 2022 (158)
  5. 2021 (148)
  6. 2020 (152)

More Years

Publications
  1. Annals of Oncology (1663)

Results (1663)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
    Meeting Abstract

    Nabell, L.; Ho, A. L.; Posner, M. R.; Neupane, P.; Naqash, A. R.; Wong, S.; Niu, J. J.; Pearson, A. T.; Laux, D.; Adkins, D. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
    Meeting Abstract

    Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFb inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J.; Zandberg, D. P.; Wong, D. J.; Yilmaz, E.; Sherman, E. J.; Calvo, A. H.; Sacco, A. G.; Bohr, D.; Reiners, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
    Meeting Abstract

    Ferrarotto, R.; Bobbili, P.; Bowles, D. W.; Even, C.; Gordon, G.; Gutierrez, A.; Metcalf, R.; Muzaffar, J.; Nguyen, C.; Oliva, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial
    Meeting Abstract

    Michel, L.; Jimeno, A.; Sukari, A.; Beck, T.; Chiu, J. W. Y.; Ahern, E. S.; Hilton, J.; Hollebecque, A.; Zanetta, S.; Patel, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
    Meeting Abstract

    Berger, J. M.; Kienzle, A.; Hatziioannou, T.; Tomasich, E.; Mayerhoefer, M.; Kiesewetter-Wiederkehr, B.; Berghoff, A. S.; Preusser, M.; Raderer, M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients
    Meeting Abstract

    Diplas, B. H.; Brown, D.; Pei, X.; Graybill, C.; Novaj, A.; Korn, W. M.; Daber, R.; Humm, J.; Shukla-Dave, A.; Schoder, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save